Every material Form 8-K Globe Life has filed with the SEC since November 19, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Globe Life reported third quarter 2026 results with diluted net income of $4.62 per share, down from $4.73 a year earlier, while net operating income rose to $4.84 per share from $4.81. The company adjusted its full-year 2026 earnings guidance to $15.35 to $15.65 per share, citing high-severity claims at Evry and a Centers for Medicare and Medicaid Services claims processing delay at its United American General Agency division, and raised its 2026 share repurchase expectation to $725 million to $775 million.
Q3 2026 net income was $361.1 million, compared with $387.8 million in Q3 2025; total premium revenue rose 7% to $1.31 billion.
Health underwriting margin at United American was a loss of $6.4 million, reflecting an Evry underwriting loss of about $16 million and about $7 million of excess Medicare Supplement claims.
Full-year 2026 earnings guidance was adjusted to $15.35 to $15.65 per share; the company estimates 2027 net operating income of $16.10 to $17.10 per share.
During Q3 2026 the company repurchased 1.1 million shares for $185 million, and now expects 2026 repurchases of $725 million to $775 million, up from $670 million to $700 million.
Globe Life Inc. disclosed that director David A. Rodriguez retired from its Board of Directors effective immediately on August 4, 2026, citing personal reasons. The company said the departure was not due to any disagreement over its operations, policies or practices.
Retirement effective immediately, as of August 4, 2026
Reason given: personal reasons
Company states no disagreement with management or the board on operations, policies or practices
Disclosed in an 8-K filed August 7, 2026 under Item 5.02
Globe Life reported second quarter 2026 net income of $3.65 per diluted share, up from $3.05 a year earlier, and net operating income of $3.61 per share, up from $3.27. The company raised its full-year 2026 earnings guidance to $15.55 to $15.95 per share, an increase of $0.10 at the midpoint.
Q2 2026 net income was $3.65 per diluted share vs. $3.05 in Q2 2025, up 20%.
Q2 2026 net operating income was $3.61 per diluted share vs. $3.27, up 10%.
Full-year 2026 EPS guidance raised to $15.55 to $15.95, up $0.10 at the midpoint.
The company repurchased 1.1 million shares for $175 million during the quarter.
Globe Life signed a new $450 million term loan and a third amended credit agreement on June 26, 2026, with Wells Fargo replacing Bank of America as administrative agent. The filing shows the company extended its borrowing arrangements, with the term loan maturity moved to June 26, 2029 and the credit agreement maturity moved to June 26, 2031.
Term loan principal increased from $250 million to $450 million, with maturity extended from August 15, 2027 to June 26, 2029.
Credit agreement maturity extended from March 29, 2029 to June 26, 2031.
Wells Fargo, National Association replaces Bank of America, N.A. as administrative agent under both agreements.
The filing does not state the credit agreement's total commitment amount.
At its April 30, 2026 annual meeting, Globe Life shareholders elected all 12 director nominees to one-year terms, approved the 2026 Incentive Plan and 2025 executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as auditor for 2026. Directors Linda L. Addison and Marilyn A. Alexander retired from the board at the meeting. The votes are routine governance matters and the filing reports no financial results.
Shareholders elected all 12 director nominees to one-year terms at the April 30, 2026 annual meeting.
Say-on-pay: 55,385,745 votes for and 6,887,045 against the 2025 executive compensation.
2026 Incentive Plan: 57,917,710 votes for and 4,271,772 against.
Deloitte & Touche LLP ratified as 2026 independent auditor with 67,622,465 votes for and 3,212,321 against.
Globe Life reported first quarter 2026 net income of $3.39 per diluted share, up from $3.01 a year earlier, and net operating income of $3.43 per diluted share, up from $3.07. The company also raised its full-year 2026 earnings guidance to a range of $15.40 to $15.90, an increase of $0.35 at the midpoint.
Q1 2026 net income was $3.39 per diluted share versus $3.01 a year earlier, an increase of 13%.
Q1 2026 net operating income was $3.43 per diluted share versus $3.07, an increase of 12%.
Full-year 2026 earnings guidance was raised to $15.40 to $15.90, up $0.35 at the midpoint.
The company repurchased 1.4 million shares in the quarter for a total cost of $203 million.
Globe Life's board voted on February 25, 2026 to expand its size from twelve to fourteen directors and appointed Derek T. Kan and Sandra L. Phillips to the new seats. The filing says both will serve until the April 30, 2026 annual meeting and receive standard non-employee director compensation, which matters to shareholders mainly as a governance change rather than a financial one.
Board expanded from twelve to fourteen directors, effective February 25, 2026
Derek T. Kan appointed to the Audit Committee; Sandra L. Phillips to the Governance and Nominating Committee
Each new director gets a $110,000 prorated annual cash retainer and a $190,000 prorated annual equity retainer; Kan also receives a $12,500 Audit Committee retainer
Globe Life reported fourth quarter 2025 net operating income of $3.39 per diluted share, up from $3.14 a year earlier, and net income of $3.29 per share, up from $3.01. The company also raised its 2026 net operating income guidance to $14.95 to $15.65 per diluted share, which matters to shareholders because it signals higher expected profit for the coming year.
Q4 2025 net operating income was $3.39 per diluted share versus $3.14 a year earlier, up 8%.
Full-year 2025 net operating income was $14.52 per diluted share versus $12.37 in 2024, above the midpoint of prior guidance.
2026 net operating income guidance is $14.95 to $15.65 per diluted share, an increase from previous guidance.
Life net sales rose 11% in the quarter, and health net sales rose 71%.
Globe Life Inc. amended its Supplemental Executive Retirement Plan on November 5, 2025, changing early retirement reduction factors for participants who retire before 65. The amendment also sets benefit terms for participants who suffer a qualifying termination during a change-of-control protection period. The filing does not disclose any financial figures, and the change affects executive pension benefits rather than company results.
Amendment dated November 5, 2025 revises early retirement reduction factors, from 50% at age 55 to 100% at age 65.
Participants in the Executive Severance Plan who have a qualifying termination during a change-of-control protection period are deemed vested and eligible for retirement income.
In those cases, retirement age is deemed at least 55, and no additional credited service is added to pension or SERP benefits.
Globe Life reported third quarter 2025 results on October 22, 2025, with net income of $4.73 per diluted share, up from $3.44 a year earlier, and net operating income of $4.81 per diluted share, up from $3.49. The company also gave 2025 net operating income guidance of $14.40 to $14.60 per diluted share and a 2026 range of $14.60 to $15.30 per share, which shareholders can compare with their own expectations. The results include a $134.3 million pre-tax remeasurement gain from updated assumptions, compared with $46.3 million a year earlier.
Q3 2025 net income was $387.8 million, or $4.73 per diluted share, versus $3.44 in Q3 2024.
Net operating income was $4.81 per diluted share, up 38% from $3.49, per the release.
Insurance underwriting income rose 30% to $503.1 million; life underwriting margin rose 24%.
2025 net operating income guidance is $14.40 to $14.60 per diluted share; 2026 guidance is $14.60 to $15.30.
Globe Life reported second quarter 2025 net income of $3.05 per diluted share, up from $2.83 a year earlier, and net operating income of $3.27 per diluted share, up from $2.97. The company reaffirmed its full-year 2025 guidance of $14.25 to $14.65 per diluted share in net operating income, and it repurchased 1.9 million shares for $226 million during the quarter.
Net income per diluted share was $3.05 for the quarter ended June 30, 2025, versus $2.83 a year earlier; net operating income per diluted share was $3.27, versus $2.97.
Total net income was $252.7 million, compared with $258.4 million in the second quarter of 2024.
Total revenue was $1.48 billion, up from $1.44 billion a year earlier.
The company reaffirmed 2025 net operating income guidance of $14.25 to $14.65 per diluted share.
Globe Life Inc. reported first quarter 2025 net income of $3.01 per diluted share, up from $2.67 a year earlier, and net operating income of $3.07 per diluted share, up from $2.78. The company reaffirmed its 2025 net operating income guidance of $13.45 to $14.05 per diluted share, and repurchased 1.5 million shares for $177 million during the quarter.
Net income of $3.01 per diluted share vs. $2.67 a year earlier; net operating income of $3.07 vs. $2.78, up 10%
Total insurance premium revenue rose 5% to $1.20 billion for the quarter ended March 31, 2025
Repurchased 1.5 million shares at a total cost of $177 million during the quarter
2025 net operating income guidance of $13.45 to $14.05 per diluted share reaffirmed
Steven P. Johnson retired from the Globe Life Inc. Board of Directors at the Annual Meeting of Shareholders on April 24, 2025. At the same meeting, shareholders elected all 12 director nominees, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as independent auditor for 2025.
Steven P. Johnson retired from the board at the April 24, 2025 annual meeting.
Each of the 12 director nominees received more For votes than Against votes; the lowest For count was 63,028,765 (J. Matthew Darden).
Advisory say-on-pay vote on 2024 executive compensation: 61,266,023 For and 5,190,749 Against.
Deloitte & Touche LLP ratified as 2025 independent auditor with 70,767,706 For and 3,748,866 Against.
Globe Life's board expanded from eleven to thirteen directors on February 26, 2025, and appointed Matthew J. Adams and Philip M. Jacobs to the newly created seats. Both were determined to be independent and named to the Audit Committee, and their terms run until the April 24, 2025 Annual Meeting of Shareholders. The filing describes routine board additions and standard director pay rather than any change in company operations or finances.
Board expanded from eleven to thirteen directors effective February 26, 2025
Matthew J. Adams and Philip M. Jacobs appointed; initial terms end at the April 24, 2025 Annual Meeting
Both named to the Audit Committee; each receives a $100,000 prorated annual cash retainer and a $180,000 prorated equity retainer, plus a $12,500 Audit Committee retainer
Globe Life reported fourth quarter 2024 results on February 5, 2025, with net income of $3.01 per diluted share, up from $2.88, and net operating income of $3.14, up 12% from $2.80. The company also projected 2025 net operating income of $13.45 to $14.05 per diluted share, which gives shareholders a range for expected earnings in the coming year.
Q4 2024 net income was $3.01 per diluted share, versus $2.88 a year earlier; net operating income was $3.14 versus $2.80.
Full-year 2024 net income was $11.94 per diluted share, versus $10.07; full-year net operating income was $12.37 versus $10.65.
2025 guidance: net operating income of $13.45 to $14.05 per diluted share for the year ending December 31, 2025.
Q4 legal proceedings reduced net income by $12.5 million after tax, compared with $711 thousand a year earlier.
Globe Life's board adopted an Executive Severance Plan on November 13, 2024, covering Co-CEOs and other Named Executive Officers, and amended its equity award agreement forms. The plan sets cash severance, health coverage and outplacement benefits for qualifying terminations, with larger payments if termination occurs within 24 months after a change in control.
Co-CEOs receive cash severance of 2.0 times base salary plus target annual bonus, paid over 24 months, for terminations outside a change-in-control period
Other eligible executives receive 1.5 times base salary plus target bonus, paid over 18 months, outside a change-in-control period
Within 24 months after a change in control, eligible executives receive a lump sum of 2 times base salary plus target bonus, plus 24 months of health premium payments
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Globe Life filing is on SEC EDGAR ↗. 8-K briefs of other companies →